JP2020526501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526501A5 JP2020526501A5 JP2019572475A JP2019572475A JP2020526501A5 JP 2020526501 A5 JP2020526501 A5 JP 2020526501A5 JP 2019572475 A JP2019572475 A JP 2019572475A JP 2019572475 A JP2019572475 A JP 2019572475A JP 2020526501 A5 JP2020526501 A5 JP 2020526501A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- methyl
- difluoroacetamide
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 93
- -1 2,6-dioxopiperidin-3-yl Chemical group 0.000 claims description 42
- 229940125904 compound 1 Drugs 0.000 claims description 41
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 34
- 229940002612 prodrug Drugs 0.000 claims description 31
- 239000000651 prodrug Substances 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 31
- 239000012453 solvate Substances 0.000 claims description 31
- 239000013078 crystal Substances 0.000 claims description 26
- 241000124008 Mammalia Species 0.000 claims description 25
- 150000004677 hydrates Chemical class 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 21
- 208000032839 leukemia Diseases 0.000 claims description 21
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims description 13
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims description 10
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 8
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 8
- 108700028369 Alleles Proteins 0.000 claims description 5
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 5
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 5
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 claims description 4
- 101000864057 Homo sapiens Serine/threonine-protein kinase SMG1 Proteins 0.000 claims description 4
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 claims description 4
- 102100029938 Serine/threonine-protein kinase SMG1 Human genes 0.000 claims description 4
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 4
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 201000010987 breast neuroendocrine neoplasm Diseases 0.000 claims description 3
- 239000007979 citrate buffer Substances 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 102100036816 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A Human genes 0.000 claims description 2
- 101000851788 Homo sapiens Eukaryotic peptide chain release factor GTP-binding subunit ERF3A Proteins 0.000 claims description 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- GMYLVKUGJMYTFB-UHFFFAOYSA-N 5-ethyl-3-[2-methyl-6-(1h-1,2,4-triazol-5-yl)pyridin-3-yl]-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound N1=C2N(CC)C(=O)CNC2=NC=C1C(C(=N1)C)=CC=C1C1=NN=CN1 GMYLVKUGJMYTFB-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 60
- 238000000034 method Methods 0.000 description 45
- 239000013011 aqueous formulation Substances 0.000 description 20
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 7
- 229960005167 everolimus Drugs 0.000 description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 4
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 4
- 239000004012 Tofacitinib Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229950000971 baricitinib Drugs 0.000 description 4
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 4
- 229950003487 fedratinib Drugs 0.000 description 4
- 229950006663 filgotinib Drugs 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- UQTPDWDAYHAZNT-AWEZNQCLSA-N ilginatinib Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2=CN(C)N=C2)=CC=1NC1=CN=CC=N1 UQTPDWDAYHAZNT-AWEZNQCLSA-N 0.000 description 4
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 4
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 4
- 229950011410 pacritinib Drugs 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 229960000215 ruxolitinib Drugs 0.000 description 4
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 4
- 229960001350 tofacitinib Drugs 0.000 description 4
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 4
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PWBHUSLMHZLGRN-UHFFFAOYSA-N 2-(4-chlorophenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2,2-difluoroacetamide Chemical compound ClC1=CC=C(C=C1)C(C(=O)NCC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)(F)F PWBHUSLMHZLGRN-UHFFFAOYSA-N 0.000 description 3
- 239000012824 ERK inhibitor Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- ZMIBIIAWFMCVFD-UHFFFAOYSA-N 2,2-difluoroacetamide Chemical compound NC(=O)C(F)F ZMIBIIAWFMCVFD-UHFFFAOYSA-N 0.000 description 2
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 2
- MKPIEWCXDDBSKH-UHFFFAOYSA-N 2-[2-(trifluoromethyl)pyridin-4-yl]-1,3,5-triazine Chemical compound FC(C1=NC=CC(=C1)C1=NC=NC=N1)(F)F MKPIEWCXDDBSKH-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100039064 Interleukin-3 Human genes 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000011360 adjunctive therapy Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000012931 lyophilized formulation Substances 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 229950010895 midostaurin Drugs 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 2
- 229950001457 pexidartinib Drugs 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229950001626 quizartinib Drugs 0.000 description 2
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical group O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 2
- 229960001183 venetoclax Drugs 0.000 description 2
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229940125763 bromodomain inhibitor Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
Images
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023080568A JP2023113681A (ja) | 2017-06-30 | 2023-05-16 | ２－（４－クロロフェニル）－ｎ－｛［２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル］メチル｝－２，２－ジフルオロアセトアミドの組成物及び使用法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527744P | 2017-06-30 | 2017-06-30 | |
| US62/527,744 | 2017-06-30 | ||
| US201862653436P | 2018-04-05 | 2018-04-05 | |
| US62/653,436 | 2018-04-05 | ||
| US201862673064P | 2018-05-17 | 2018-05-17 | |
| US62/673,064 | 2018-05-17 | ||
| PCT/US2018/040286 WO2019006299A1 (en) | 2017-06-30 | 2018-06-29 | COMPOSITIONS AND METHODS FOR THE USE OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023080568A Division JP2023113681A (ja) | 2017-06-30 | 2023-05-16 | ２－（４－クロロフェニル）－ｎ－｛［２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル］メチル｝－２，２－ジフルオロアセトアミドの組成物及び使用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020526501A JP2020526501A (ja) | 2020-08-31 |
| JP2020526501A5 true JP2020526501A5 (enExample) | 2021-08-26 |
Family
ID=64741897
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572475A Pending JP2020526501A (ja) | 2017-06-30 | 2018-06-29 | ２−（４−クロロフェニル）−ｎ−｛［２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−５−イル］メチル｝−２，２−ジフルオロアセトアミドの組成物及び使用法 |
| JP2023080568A Pending JP2023113681A (ja) | 2017-06-30 | 2023-05-16 | ２－（４－クロロフェニル）－ｎ－｛［２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル］メチル｝－２，２－ジフルオロアセトアミドの組成物及び使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023080568A Pending JP2023113681A (ja) | 2017-06-30 | 2023-05-16 | ２－（４－クロロフェニル）－ｎ－｛［２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル］メチル｝－２，２－ジフルオロアセトアミドの組成物及び使用法 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20190030018A1 (enExample) |
| EP (2) | EP3644999B1 (enExample) |
| JP (2) | JP2020526501A (enExample) |
| KR (1) | KR20200020899A (enExample) |
| CN (1) | CN111032043A (enExample) |
| AU (1) | AU2018294327A1 (enExample) |
| BR (1) | BR112019028101A2 (enExample) |
| CA (1) | CA3068591A1 (enExample) |
| CL (1) | CL2019003857A1 (enExample) |
| DK (1) | DK3644999T3 (enExample) |
| ES (1) | ES2939739T3 (enExample) |
| FI (1) | FI3644999T3 (enExample) |
| HR (1) | HRP20230210T1 (enExample) |
| HU (1) | HUE061356T2 (enExample) |
| IL (1) | IL271726A (enExample) |
| LT (1) | LT3644999T (enExample) |
| MX (2) | MX2019015886A (enExample) |
| PL (1) | PL3644999T3 (enExample) |
| PT (1) | PT3644999T (enExample) |
| RS (1) | RS64029B1 (enExample) |
| SG (1) | SG11201913008TA (enExample) |
| SI (1) | SI3644999T1 (enExample) |
| SM (1) | SMT202300068T1 (enExample) |
| WO (1) | WO2019006299A1 (enExample) |
| ZA (1) | ZA201908605B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018276611B2 (en) | 2017-05-31 | 2022-01-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| FI3908281T3 (fi) * | 2019-01-09 | 2024-10-01 | Celgene Corp | Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa |
| JP2022537551A (ja) | 2019-06-20 | 2022-08-26 | セルジーン・クオンティセル・リサーチ・インコーポレイテッド | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| WO2021086829A1 (en) * | 2019-10-28 | 2021-05-06 | Celgene Corporation | Methods for treating leukemia and use of a leukemic stem cell signature to predict clinical sensitivity to therapies |
| WO2021086830A1 (en) * | 2019-10-28 | 2021-05-06 | Celgene Corporation | Use of biomarkers to predict clinical sensitivity to 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| WO2021095835A1 (en) * | 2019-11-13 | 2021-05-20 | Taiho Pharmaceutical Co., Ltd. | Novel salt of terphenyl compound |
| EP4121051A4 (en) * | 2020-03-16 | 2024-04-17 | Celgene Corporation | COMBINATION THERAPY FOR ACUTE MYELOID LEUKEMIA |
| JP2023545274A (ja) * | 2020-10-07 | 2023-10-27 | クルゲン（シャンハイ），インク． | 癌を処置する化合物および方法 |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| CN113125602A (zh) * | 2021-04-16 | 2021-07-16 | 山东铂源药业有限公司 | 一种哌柏西利中残留溶剂的检测方法 |
| WO2024015855A1 (en) * | 2022-07-13 | 2024-01-18 | Monte Rosa Therapeutics, Inc. | COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS |
| TW202423434A (zh) * | 2022-10-07 | 2024-06-16 | 瑞士商歐庫利斯營運股份有限公司 | mTOR抑制劑的點眼劑微懸液 |
| US12357645B2 (en) | 2023-03-09 | 2025-07-15 | Minneamrita Therapeutics Llc | Drug combination for treatment of gastric cancer |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0011312A1 (en) | 1977-07-09 | 1980-05-28 | LUCAS INDUSTRIES public limited company | Road vehicle electrical systems |
| DE2848746A1 (de) | 1978-11-10 | 1980-05-22 | Wolfgang Arheiliger | Dichtung fuer eine schwellenlose tuere mit drehfluegel |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9126209D0 (en) * | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| PE20142098A1 (es) | 2012-01-06 | 2015-01-08 | Agios Pharmaceuticals Inc | Compuestos terapeuticamente activos y sus metodos de uso |
| AU2013299627C1 (en) * | 2012-08-09 | 2018-05-31 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| AU2014287122B9 (en) | 2013-07-11 | 2018-11-01 | Les Laboratoires Servier | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer |
| CN105593215B (zh) | 2013-07-11 | 2019-01-15 | 安吉奥斯医药品有限公司 | 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物 |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| AU2014295938B2 (en) | 2013-08-02 | 2018-07-19 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
| TW201540323A (zh) * | 2014-01-15 | 2015-11-01 | Celgene Corp | ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物 |
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| WO2017120415A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| CN108601777B (zh) * | 2016-01-08 | 2021-08-03 | 细胞基因公司 | 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的制剂 |
-
2018
- 2018-06-29 KR KR1020207002231A patent/KR20200020899A/ko not_active Withdrawn
- 2018-06-29 US US16/024,581 patent/US20190030018A1/en not_active Abandoned
- 2018-06-29 WO PCT/US2018/040286 patent/WO2019006299A1/en not_active Ceased
- 2018-06-29 DK DK18823719.2T patent/DK3644999T3/da active
- 2018-06-29 AU AU2018294327A patent/AU2018294327A1/en not_active Abandoned
- 2018-06-29 LT LTEPPCT/US2018/040286T patent/LT3644999T/lt unknown
- 2018-06-29 CN CN201880056213.2A patent/CN111032043A/zh active Pending
- 2018-06-29 CA CA3068591A patent/CA3068591A1/en active Pending
- 2018-06-29 SG SG11201913008TA patent/SG11201913008TA/en unknown
- 2018-06-29 MX MX2019015886A patent/MX2019015886A/es unknown
- 2018-06-29 ES ES18823719T patent/ES2939739T3/es active Active
- 2018-06-29 RS RS20230153A patent/RS64029B1/sr unknown
- 2018-06-29 SI SI201830859T patent/SI3644999T1/sl unknown
- 2018-06-29 HR HRP20230210TT patent/HRP20230210T1/hr unknown
- 2018-06-29 FI FIEP18823719.2T patent/FI3644999T3/fi active
- 2018-06-29 EP EP18823719.2A patent/EP3644999B1/en active Active
- 2018-06-29 JP JP2019572475A patent/JP2020526501A/ja active Pending
- 2018-06-29 PT PT188237192T patent/PT3644999T/pt unknown
- 2018-06-29 EP EP22212562.7A patent/EP4201399A3/en not_active Withdrawn
- 2018-06-29 PL PL18823719.2T patent/PL3644999T3/pl unknown
- 2018-06-29 BR BR112019028101-0A patent/BR112019028101A2/pt not_active Application Discontinuation
- 2018-06-29 SM SM20230068T patent/SMT202300068T1/it unknown
- 2018-06-29 HU HUE18823719A patent/HUE061356T2/hu unknown
-
2019
- 2019-12-20 MX MX2022001410A patent/MX2022001410A/es unknown
- 2019-12-23 ZA ZA2019/08605A patent/ZA201908605B/en unknown
- 2019-12-26 CL CL2019003857A patent/CL2019003857A1/es unknown
- 2019-12-26 IL IL271726A patent/IL271726A/en unknown
-
2023
- 2023-05-16 JP JP2023080568A patent/JP2023113681A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526501A5 (enExample) | ||
| JP7502368B2 (ja) | ６－（２－ヒドロキシ－２－メチルプロポキシ）－４－（６－（６－（（６－メトキシピリジン－３－イル）メチル）－３，６－ジアザビシクロ［３．１．１］ヘプタン－３－イル）ピリジン－３－イル）ピラゾロ［１，５－ａ］ピリジン－３－カルボニトリルを含む製剤 | |
| US10301280B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| Listro et al. | Urea-based anticancer agents. Exploring 100-years of research with an eye to the future | |
| CN105793260B (zh) | 作为用于治疗癌症的raf抑制剂的1‑(5‑叔丁基‑2‑芳基‑吡唑‑3‑基)‑3‑[2‑氟‑4‑[(3‑氧代‑4h‑吡啶并[2，3‑b]吡嗪‑8‑基)氧基]苯基]脲衍生物 | |
| US20190134033A1 (en) | Pharmaceutical combinations | |
| TWI406662B (zh) | 可用於治療過度增殖疾病及伴隨血管生成的疾病之經取代的２，３-二氫咪唑并〔１，２-ｃ〕喹唑啉衍生物 | |
| WO2023190748A1 (ja) | 腫瘍治療用医薬組成物 | |
| Yang et al. | Structure–activity relationship studies of pyrazolo [3, 4-d] pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo | |
| AU2014317119B2 (en) | Combination of a MEK inhibitor and an ERK inhibitor for use in treatment of hyperproliferative diseases | |
| US10047078B2 (en) | Aminothiazole compounds | |
| JP2019077727A (ja) | 癌の処置のための組成物 | |
| US20120316137A1 (en) | Methods and Compositions for Treating Cancer | |
| JP2022515670A5 (enExample) | ||
| KR20180052757A (ko) | 헤테로시클릭 화합물 및 그의 용도 | |
| CN102695417A (zh) | 用于激酶调节的化合物和方法及其适应症 | |
| CN104981247A (zh) | 用于激酶调节的化合物和方法及其适应症 | |
| US20150080372A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| EP3706746A1 (en) | A combination therapy with apatinib for the treatment of cancer | |
| JP2022521380A (ja) | Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物 | |
| ES2956411T3 (es) | Combinaciones farmacéuticas | |
| CN114302878A (zh) | 酪氨酸激酶非受体1(tnk1)抑制剂及其用途 | |
| NO325454B1 (no) | Anvendelse av N-{5-[4-(4-metyl-piperazino-metyl)-benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidin-amin. | |
| KR20200102948A (ko) | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 | |
| TW201636350A (zh) | 作為激酶調節劑之三唑並嗒 |